How do you pay?

How to pay the least

Ask for the cash price

Jascayd

We didn’t find one.

  1. Ask your pharmacy for Jascayd’s cash price, and one or two other pharmacies too.
  2. Jascayd’s savings card works only with insurance from a job or one you bought.

Free from the maker, if you qualify Boehringer Ingelheim Cares Foundation Patient Assistance Program. Or call 1-800-556-8317.

See if you qualify 

Compare every option

Question
Brand nameJascayd
Authorized genericnerandomilast
Regular genericnerandomilast
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldNone found
Same as Jascayd?
The original
–
–

Brand nameThe maker’s card

JASCAYD Copay Savings Program

Savings card from Boehringer Ingelheim

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a month

Sign up on patient.boehringer-ingelheim.com 

In the maker’s words

“With the JASCAYD Copay Savings program, eligible patients prescribed JASCAYD can pay as little as $0 per month.”

From the maker’s offer on patient.boehringer-ingelheim.com, checked October 27, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Jascayd itself, from the same company, sold without the brand name, and usually for less. For now Jascayd is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

JASCAYD is a phosphodiesterase 4 (PDE4) inhibitor indicated for:

  • The treatment of idiopathic pulmonary fibrosis in adult patients.
  • The treatment of progressive pulmonary fibrosis in adult patients.

Source: the FDA label for Jascayd (Boehringer Ingelheim Pharmaceuticals, Inc.), August 14, 2026. Full label on DailyMed 

Good to know